CORT
$49.49
Revenue | $163.8Mn |
Net Profits | $35.49Mn |
Net Profit Margins | 21.67% |
PE Ratio | 44.03 |
Corcept Therapeutics Inc’s revenue jumped 39.15% since last year same period to $163.8Mn in the Q2 2024. On a quarterly growth basis, Corcept Therapeutics Inc has generated 11.57% jump in its revenue since last 3-months.
Corcept Therapeutics Inc’s net profit jumped 28.92% since last year same period to $35.49Mn in the Q2 2024. On a quarterly growth basis, Corcept Therapeutics Inc has generated 27.83% jump in its net profits since last 3-months.
Corcept Therapeutics Inc’s net profit margin fell -7.35% since last year same period to 21.67% in the Q2 2024. On a quarterly growth basis, Corcept Therapeutics Inc has generated 14.57% jump in its net profit margins since last 3-months.
Corcept Therapeutics Inc’s price-to-earnings ratio after this Q2 2024 earnings stands at 44.03.
EPS Estimate Current Quarter | 0.28 |
EPS Estimate Current Year | 0.28 |
Corcept Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at 0.28 - a 21.74% jump from last quarter’s estimates.
Corcept Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at 0.28.
Earning Per Share (EPS) | 0.32 |
Return on Assets (ROA) | 0.13 |
Return on Equity (ROE) | 0.25 |
Corcept Therapeutics Inc’s earning per share (EPS) jumped 28% since last year same period to 0.32 in the Q2 2024. This indicates that the Corcept Therapeutics Inc has generated 28% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Corcept Therapeutics Inc’s return on assets (ROA) stands at 0.13.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Corcept Therapeutics Inc’s return on equity (ROE) stands at 0.25.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2024-07-29 | 0.23 | 0.32 | 39.13% |
2024-05-01 | 0.22 | 0.25 | 13.64% |